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Abstract
Objective: To investigate associations between prostate cancer and sexually transmitted diseases (STDs), prostatitis,
benign prostatic hyperplasia (BPH), and vasectomy in a population-based case–control study in Wayne County,
Michigan, among African American and white men aged 50–74 years.
Methods: Incident prostate cancer cases (n¼ 700) from 1996–1998 were identified from the Metropolitan Detroit
Cancer Surveillance System. Controls (n¼ 604) were identified through random digit dialing and Medicare recipient
lists, and frequency matched to cases on age and race. History of potential prostate cancer risk factors was
ascertained through in-person interview.
Results: Prostate cancer was not associated with STD or vasectomy history. History of prostatitis was associated
with prostate cancer among all subjects (odds ratio [OR]¼ 1.8, 95% confidence interval [CI]: 1.1, 2.9) and in African
American men (OR¼ 2.2, 95% CI: 1.1, 4.6). History of BPH was associated with prostate cancer among all subjects
(OR¼ 2.4, 95% CI: 1.8, 3.3); significant associations were observed in both African American (OR¼ 2.7, 95% CI:
1.6, 4.4) and white (OR¼ 2.3, 95% CI: 1.5, 3.4) men.
Conclusions: Among all subjects, prostate cancer was associated with prostatitis and BPH history, but not with STD
or vasectomy history. Prevention efforts could be enhanced if inflammatory or infectious etiologies are found to be
of importance in the subsequent development of prostate cancer.
Introduction
Prostate cancer is the most commonly diagnosed noncu-
taneous cancer and the second leading cause of cancer
deaths in men in the United States [1]. It is estimated that
one in every five American men will be affected by this
disease [2]. Racial variations in incidence and mortality
rates of prostate cancer are striking: African American
men have the highest age-adjusted incidence rate of
prostate cancer in theworld (185.7 per 100,000),markedly
higher than that ofU.S. whitemen (110 per 100,000), with
a mortality rate more than twice that of white men [3, 4].
Despite the considerable disease burden, relatively
little is known about risk factors for prostate cancer or
reasons for racial and ethnic differentials in risk.
Epidemiologic studies of numerous putative risk factors
for prostate cancer (including diet, body mass index
(BMI), smoking, alcohol consumption, and physical
activity) have been conducted, with inconsistent find-
ings. The only well established risk factors for prostate
cancer include age, race, and a family history of prostate
cancer [5].
Recent studies have explored the contribution of
sexually transmitted diseases (STDs) to the development
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of prostate malignancy. Specific STD agents have been
associated inconsistently with prostate cancer, with
positive associations reported with gonorrhea [6, 7],
syphilis [7], and human papilloma virus (HPV) [8, 9].
Recent national data suggest that African Americans
have substantially higher rates of STDs than other racial
and ethnic groups in the United States [10, 11]. The
possible influence of STDs has been suggested as a
partial explanation for the higher rates of prostate
cancer among African Americans [12], however, this
relationship has not been well characterized.
Associations between urogenital conditions other
than STDs and prostate cancer have also been studied,
with inconsistent results. Prostatitis, a commonly occur-
ring inflammation or infection of the prostate, is an
important cause of morbidity in adult males [13–16].
Most previous case–control studies examining prostati-
tis and prostate cancer did not report significant
associations [17–21]; however, Honda et al. reported
an increased risk (OR¼ 2.2; 95% CI: 1.2, 4.3) [22].
Benign prostatic hyperplasia (BPH) is another highly
prevalent condition among middle-aged and elderly men
[23], but findings from epidemiologic studies of the
association between BPH and prostate cancer have been
inconsistent [24–27].
Men who have undergone vasectomy have been
shown to have a moderately higher risk of prostate
cancer in some studies [28–33], while other studies have
reported no association [17, 20, 22, 34–39]. Because the
prevalence of male sterilization (approximately 11%)
has remained relatively stable in the U.S. since 1982 [40]
and, worldwide, an estimated 42–60 million couples rely
on vasectomy for contraception [38], any association of
vasectomy with prostate cancer would be of importance.
This report is based on men in the metropolitan
Detroit area who participated in a population-based
case–control study of occupational risk factors for
prostate cancer. The primary focus of this case–control
study was to examine associations between occupational
exposures and prostate cancer; the secondary analysis
presented here considers associations of prostate cancer
with a history of STD and other urogenital conditions,
including prostatitis, BPH, and vasectomy.
Materials and methods
Case and control ascertainment
Cases were identified through the Metropolitan Detroit
Cancer Surveillance System (MDCSS), a population-
based cancer registry established in the 1950s, and a
founding member of the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER)
Program since 1973. Because of the large volume of
prostate cancer cases reported in the MDCSS registry
(exceeding sample size requirements), a random sample
of half of all malignant prostate cancer cases diagnosed
between April 1, 1996 and March 30, 1998 were
identified. Eligible cases included those with histologi-
cally confirmed adenocarcinoma of the prostate (ICD-O
topography code C61.9 [41]), aged 50–74 years, residing
in Wayne County at the time of diagnosis, who spoke
English and had a working telephone number. Wayne
County, which includes the city of Detroit, was selected
because of the high proportion of African American
residents (over 40%). The physician of record for each
case was sent a letter explaining the nature of the study
and inquiring whether there was any medical reason not
to contact the case. Each potential case not excluded by
his physician was sent a letter explaining the nature of
the study, and trained interviewers attempted to contact
these cases within one week of the introductory letter. If
the subject agreed to participate, arrangements were
made for an in-person interview.
Controls were initially identified through a random-
digit dialing (RDD) telephone sample of Wayne County
residents, aged 50–74 years, who spoke English and had
a working telephone number. Controls were selected by
stratified random sampling using Waksberg’s two-stage
RDD method [42] and were frequency matched to the
cases by race (white, African American, and other) and
age (in five-year intervals). To include sufficient numbers
of controls in older age groups, a random sample of
Medicare recipients aged 65–74 years with working
telephone numbers obtained from a Health Care
Financing Administration (HCFA) listing was also
used. Potential controls were sent introductory letters
similar to those sent to potential cases requesting
participation. The study protocol and consent form
were approved by the Wayne State University Human
Investigation Committee and all subjects provided
written informed consent prior to the interview.
Interview
Trained interviewers asked cases and controls about
demographics, medical history, family medical history,
physical activity, lifestyle factors, household exposures,
and occupational history using a structured question-
naire. Within the medical history section, subjects were
asked to self-report their past history of four specific
STDs (gonorrhea, syphilis, chancroid, genital herpes) or
‘‘other’’ STDs, and urogenital conditions other than
STDs, including prostatitis, BPH, and vasectomy. Sub-
jects were also asked to report their past history of
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transurethral resection of the prostate (TURP), a
common surgical treatment for BPH. Exposures were
assessed for the period before a specified reference date,
which was the date of diagnosis for cases and the date of
study entry for controls.
Cases were compared to controls to determine whether
the two groups differed according to matching variables,
subject characteristics (including marital status, educa-
tion, current BMI, cigarette use prior to reference date,
average weekly number of alcoholic drinks in the
previous year, and family history of prostate cancer),
and risk factors of interest. A positive family history of
prostate cancer (in first degree relatives only) was defined
as self-reported history of prostate cancer in the subject’s
father and/or brother(s). History of specific STDs was
based on self-report; in addition, a positive history of
‘‘any STD’’ was defined by self-reported history of at
least one of the four specific STDs or ‘‘other’’ STD. For
cases, tumor stage and grade were ascertained through
linkage with the MDCSS database. Tumor stage was
categorized as localized, regional (regional direct exten-
sion; regional lymph nodes; regional direct extension and
regional lymph nodes; or regional, not otherwise spec-
ified), distant, or unknown. MDCSS records tumor
grade as well differentiated (Gleason score 2–4), moder-
ately differentiated (Gleason score 5–7), poorly differ-
entiated (Gleason score 8–10), or unknown.
Statistical analysis
Comparisons of categorical variables between cases
and controls were made using two-tailed v2 tests in the
entire study sample and within African American and
white men (stratified). p-Values <0.05 were considered
statistically significant. Unconditional logistic regression
analyses were conducted to explore relationships between
urogenital conditions and prostate cancer by estimating
odds ratios (OR) and 95% confidence intervals (CI).
These analyses were first conducted in the entire sample
and then were repeated after stratifying by race to
examine potential interactions between race and each
urogenital condition. Additionally, interaction terms
between race and each urogenital condition were added
to the appropriate multivariable models and assessed for
statistical significance. Adjustments for age (as a contin-
uous variable), education level, family history of prostate
cancer (in first degree relatives only) and, where appro-
priate, race were included in all logistic regressionmodels,
because these variables were associated with either
prostate cancer or the risk factor of interest. The potential
for confounding and effect modification by other subject
characteristics was also investigated, including marital
status, current BMI, cigarette use prior to the reference
date, and average weekly number of alcoholic drinks in
the previous year; however, because the effects were not
statistically significant, these variables were not included
in the multivariable models.
We examined associations between BPH, TURP and
prostate cancer because TURP may increase the detec-
tion rate for prostate cancer. Because of the potential for
reporting bias for topics of a sensitive nature, analyses for
the associations between prostate cancer and history of
STD, prostatitis and BPH were repeated after excluding
participants who had another individual present during
their interview. Data analyses were performed using SAS
version 8.2 (SAS Institute, Cary, NC, USA) [43].
Results
Study sample
Of the 1287 men with prostate cancer who were eligible
to be cases, 730 (56.7%) completed the interview
(Table 1). Of the 557 individuals not interviewed, 78
(14.0%) died before contact could be made, 8 (1.4%)
were not contacted because their physician refused, 257
(46.1%) refused to participate, 40 (7.2%) were too ill or
hard of hearing, and 174 (31.2%) were unable to be
contacted. Analyses were limited to 700 African Amer-
ican and white cases; the 30 cases (4.1%) that identified
‘‘other’’ race or did not provide race information were
excluded. The average time interval between date of
diagnosis of cases and date of interview was
16.1 months (range: 3.1–42.2; standard deviation: 7.8).
Table 1. Potentially eligible prostate cancer cases and controls. Wayne
County, Michigan, April 1996–March 1998
Cases Controls
n % n %
Total potentially eligible men 1287 1457
Not interviewed 557 43.3 771 52.9
Physician refused (cases only) 8 1.4 a a
Subject/Family member refused 257 46.1 396 51.4
Too ill/Hard of hearing 40 7.2 45 5.8
Deceased 78 14.0 29 3.8
Unable to contact 174 31.2 301 39.0
Interviewed 730 56.7 686 47.1
Did not complete interview 0 0.0 2 0.3
Excluded after interview
History of prostate cancer
(controls only)
a a 46 6.7
Race other than African American
or White/Did not provide race
information
30 4.1 34 5.0
Eligible 700 95.9 604 88.0
aNot applicable.
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Of the 1457 total potentially eligible controls, 686
(47.1%) were interviewed (Table 1). Of the 771 individ-
uals not interviewed, 29 (3.8%) died before contact
could be made, 396 (51.4%) refused to participate, 45
(5.8%) were too ill or hard of hearing, and 301 (39.0%)
were unable to be contacted. Of the 686 individuals who
were interviewed, 2 (0.3%) did not complete the
interview, 46 (6.7%) were excluded because of a prior
diagnosis of prostate cancer, and 34 (5.0%) were
excluded because they identified ‘‘other’’ race or did
not provide race information. Analyses were thus
limited to the 604 African American and white controls
who completed an interview. Of the participating
controls, 46% were selected through RDD and 54%
through HCFA. Telephone numbers were not available
for 185 (28.4%) of the 651 randomly selected HCFA
controls; 63 (34.1%) of these were contacted door-to-
door and the remaining 122 (66.0%) were excluded. The
average time interval between date of study entry and
interview of controls was 4.5 months (range: 0–35.8;
standard deviation: 4.8).
Subject characteristics
Overall, 700 eligible prostate cancer cases diagnosed
between April 1996 and March 1998 and 604 controls
were included in the analyses (Table 2). Cases and
controls were similar with respect to marital status,
current BMI, smoking history, average weekly number
of alcoholic drinks in the previous year, and the presence
of anyone else during the interview. Overall, a greater
proportion of cases was older (p¼ 0.04), African Amer-
ican (p¼ 0.005), had attained less education (p¼ 0.03),
and had a family history of prostate cancer in first
degree relatives (p¼ 0.0004) compared to controls. A
smaller proportion of cases had a history of vasectomy
(p¼ 0.007) compared to controls. Among the 610
African American subjects, there were no significant
differences between cases and controls for any of the
characteristics presented in Table 2. Among the 694
white subjects, a greater proportion of cases was older
(p¼ 0.04) and had a family history of prostate cancer in
first degree relatives (p¼ 0.0012) compared to controls.
Table 2. Characteristics of prostate cancer cases and controls. Wayne County, Michigan, April 1996–March 1998.













n % n % n % n % n % n %
Agea,b,c
50–54 35 9.9 30 11.7 24 6.9 43 12.4 59 8.4 73 12.1
55–59 39 11.1 27 10.5 54 15.6 70 20.1 93 13.3 97 16.1
60–64 73 20.7 39 15.2 62 17.9 54 15.6 135 19.3 93 15.4
65–69 98 27.8 85 33.1 107 30.8 94 27.1 205 29.3 179 29.6
70–74 108 30.6 76 29.6 100 28.8 86 24.8 208 29.7 162 26.8
Raceb
African American 353 50.4 257 42.6
White 347 49.6 347 57.5
Marital status
Single 34 9.7 26 10.2 20 5.8 20 5.8 54 7.7 46 7.6
Married/living together 240 68.2 166 64.8 286 82.4 283 81.6 526 75.3 449 74.5
Divorced/separated 51 14.5 42 16.4 20 5.8 34 9.8 71 10.2 76 12.6
Widowed 27 7.7 22 8.6 21 6.1 10 2.9 48 6.9 32 5.3
Refused 1 1 0 0 1 1
Educationb
0–8th grade 0 0 0 0 2 0.6 0 0 2 0.3 0 0
9–11th grade 92 26.1 58 22.6 24 6.9 22 6.3 116 16.6 80 13.3
H.S. graduate 110 31.2 59 23.0 90 25.9 90 25.9 200 28.6 149 24.7
At least some college 151 42.8 140 54.5 231 66.6 235 67.7 382 54.6 375 62.1
Current body mass index
<18.5 3 0.9 1 0.4 3 0.9 2 0.6 6 0.9 3 0.5
18.5–24.9 79 22.6 60 23.4 75 21.6 91 26.4 154 22.1 151 25.1
25.0–29.9 173 49.4 123 48.1 170 49.0 160 46.4 343 49.2 283 47.1
‡30.0 95 27.1 72 28.1 99 28.5 92 26.7 194 27.8 164 27.3
Don’t know/refused 3 1 0 2 3 3
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Among cases, African Americans and whites had similar
distributions of tumor stage (p¼ 0.37) and grade
(p¼ 0.29) at diagnosis, with the majority having tumors
of localized stage (79.1%) and moderately differentiated
grade (72.6%).
Associations of STDs with prostate cancer
Overall, 25.4% of cases and 21.4% of controls reported
a history of at least one episode of STD. Among all
subjects, 42.1% of African Americans and 7.2% of
whites reported a history of at least one episode of STD.
After adjusting for age, race, education, and family
history of prostate cancer in first degree relatives,
prostate cancer was not associated with a history of
any STD, gonorrhea, genital herpes, chancroid, syphilis
or other STDs in the entire sample (Table 3). Similarly,
no significant associations between STD history and
prostate cancer were observed among African American
men or white men. No interaction between race and
Table 2. (Continued)













n % n % n % n % n % n %
Smoked > 100 cigarettes in lifetime
No 96 27.3 69 26.9 81 23.3 87 25.1 177 25.3 156 25.8
Yes 256 72.7 188 73.2 266 76.7 260 74.9 522 74.7 448 74.2
Don’t know 1 0 0 0 1 0
Alcohol use
Never 170 48.2 118 45.9 114 32.9 105 30.3 284 40.6 223 36.9
Ever 183 51.8 139 54.1 233 67.2 242 69.7 416 59.4 381 63.1
£7d 131 72.0 86 63.7 180 78.3 190 79.8 311 75.5 276 74.0
8–21d 38 20.9 30 22.2 41 17.8 40 16.8 79 19.2 70 18.8
22–56d 13 7.1 14 10.4 9 3.9 8 3.4 22 5.3 22 5.9
‡57d 0 0 5 3.7 0 0 0 0 0 0 5 1.3
Amount unknownd 1 4 3 4 4 8
Family history of prostate cancer in first degree relativesb,c,e
No 201 81.7 148 88.1 217 76.7 213 87.7 418 79.0 361 87.8
Yes 45 18.3 20 11.9 66 23.3 30 12.3 111 21.0 50 12.2
Don’t know 107 89 64 104 171 193
Vasectomy historyb
No 350 99.2 254 98.8 277 80.1 258 74.4 627 89.7 512 84.8
Yes 3 0.9 3 1.2 69 19.9 89 25.7 72 10.3 92 15.2
Don’t know 0 0 1 0 1 0
Tumor stage
Localized 281 79.6 273 78.7 554 79.1
Regional 55 15.6 62 17.9 117 16.7
Distant 10 2.8 4 1.2 14 2.0
Unknown 7 2.0 8 2.3 15 2.1
Tumor gradef
Well differentiated 19 5.4 10 2.9 29 4.1
Moderately differentiated 248 70.3 260 74.9 508 72.6
Poorly differentiated 63 17.9 59 17.0 122 17.4
Unknown 23 6.5 18 5.2 41 5.9
Anyone else present during interview
No 275 80.9 190 76.6 237 71.4 255 76.6 512 76.2 445 76.6
Yes 65 19.1 58 23.4 95 28.6 78 23.4 160 23.8 136 23.4
Not recorded by interviewer 13 9 15 14 28 23
aAge at diagnosis for cases; Age at study entry for controls.
bChi-squared p < 0.05 among all cases and controls combined (does not include don’t know or not asked).
cChi-squared p < 0.05 among white cases and controls (does not include don’t know or not asked).
dAverage weekly number of alcoholic drinks in the year before diagnosis (cases) or interview (controls).
eDefined as self-reported history of prostate cancer in subject’s father and/or brother(s).
fWell differentiated (Gleason score 2–4); moderately differentiated (Gleason score 5–7); poorly differentiated (Gleason score 8–10).
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Table 3. Adjusted odds of prostate cancer by race and history of sexually transmitted disease (STD), prostatitis, and benign prostate hyperplasia
(BPH). Wayne County, Michigan, April 1996–March 1998a
Characteristic African Americans (n = 610) Whites (n = 694) Total (n = 1304)
Cases Controls Cases Controls Cases Controls
(n = 353) (n = 257) ORb 95% CI (n = 347) (n = 347) ORb 95% CI (n = 700) (n = 604) ORc 95% CI
Any STD history
Never 196 149 1.0 320 320 1.0 516 469 1.0
Ever 155 102 1.1 0.7, 1.6 23 27 0.9 0.5, 1.8 178 129 1.0 0.7, 1.5
(%) Ever (43.9) (39.7) (6.7) (7.8) (25.4) (21.4)
(Missing) (2) (6) (4) (0) (6) (6)
Frequency of any STD
1 (referent: Never) 85 57 1.0 0.6, 1.6 17 18 1.0 0.5, 2.3 102 75 1.0 0.7, 1.6
2 36 22 1.2 0.8, 1.7 5 5 1.2 0.5, 2.5 41 27 1.2 0.8, 1.6
‡3 31 22 1.0 0.8, 1.3 1 2 0.8 0.3, 1.7 32 24 1.0 0.8, 1.2
(missing) (3) (1) (0) (2) (3) (3)
Gonorrhea history
Never 211 158 1.0 329 329 1.0 540 487 1.0
Ever 139 94 1.0 0.7, 1.6 16 18 1.1 0.5, 2.5 155 112 1.0 0.7, 1.5
(%) Ever (39.7) (37.3) (4.6) (5.2) (22.3) (18.7)
(Missing) (3) (5) (2) (0) (5) (5)
Frequency of gonorrhea
1 (referent: Never) 78 53 1.0 0.6, 1.6 15 13 1.5 0.6, 3.6 93 66 1.1 0.7, 1.6
2 31 20 1.1 0.7, 1.7 1 4 d 32 24 1.1 0.7, 1.6
‡3 27 21 1.0 0.7, 1.3 0 1 d 27 22 1.0 0.7, 1.2
(Missing) (3) (0) (0) (0) (3) (0)
Genital herpes (HSV-1 or HSV-2) history
Never 351 251 1.0 343 344 1.0 694 595 1.0
Ever 0 1 d 4 3 1.2 0.3, 5.5 4 4 1.1 0.3, 5.2
(%) Ever (0) (0.4) (1.2) (0.9) (0.6) (0.7)
(Missing) (2) (5) (0) (0) (2) (5)
Chancroid history
Never 348 251 1.0 345 346 1.0 693 597 1.0
Ever 3 3 0.2 0.02, 1.9 1 1 0.8 0.05, 13.0 4 4 0.3 0.1, 1.7
(%) Ever (0.9) (1.2) (0.3) (0.3) (0.6) (0.7)
(Missing) (2) (3) (1) (0) (3) (3)
Syphilis history
Never 325 242 1.0 346 344 1.0 671 586 1.0
Ever 24 12 1.3 0.5, 3.2 1 3 d 25 15 1.1 0.5, 2.4
(%) Ever (6.9) (4.7) (0.3) (0.9) (3.6) (2.5)
(Missing) (4) (3) (0) (0) (4) (3)
Other STDs history
Never 343 252 1.0 344 344 1.0 687 596 1.0
Ever 8 2 1.8 0.3, 9.6 2 3 0.7 0.1, 3.9 10 5 1.2 0.4, 3.8
(%) Ever (2.3) (0.8) (0.6) (0.9) (1.4) (0.8)
(Missing) (2) (3) (1) (0) (3) (3)
Prostatitis history
Never 295 238 1.0 288 320 1.0 583 558 1.0
Ever 43 15 2.2 1.1, 4.6 43 23 1.6 0.8, 2.9 86 38 1.8 1.1, 2.9
(%) Ever (12.7) (5.9) (13.0) (6.7) (12.9) (6.4)
(Missing) (15) (4) (16) (4) (31) (8)
BPH history
Never 235 211 1.0 205 281 1.0 440 492 1.0
Ever 109 39 2.7 1.6, 4.4 137 62 2.3 1.5, 3.4 246 101 2.4 1.8, 3.3
(%) Ever (31.7) (15.6) (40.1) (18.1) (35.9) (17.0)
(Missing) (9) (7) (5) (4) (14) (11)
aTable adapted from Hayes et al. [7].
bOdds ratio (OR) and 95% confidence interval (CI); ORs are adjusted for age (as a continuous variable), education, and family history of prostate
cancer (first degree relatives), and do not include subjects with missing covariate data.
cORs are adjusted for age (as a continuous variable), race, education, and family history of prostate cancer in first degree relatives, and do not include
subjects with missing covariate data.
dCould not estimate OR and 95% CI.
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history of any STD was observed (p for interaction
term¼ 0.59).
Because most men with a history of STD reported
only one episode of infection (with the exception of
gonorrhea), frequency of infection is only presented for
any STD and for gonorrhea. Both overall and within
African Americans or whites, men with one, two, or
three or more episodes of any STD did not demonstrate
higher odds of prostate cancer compared to those
without a history of any STD, after adjusting for
covariates. Similarly, no significant associations were
observed between men with one, two, or three or more
episodes of gonorrhea compared to those without a
history of gonorrhea, either overall or within African
Americans or whites.
We analyzed history of any STD by tumor stage and
grade among cases, but did not find significant differ-
ences in the distribution of STD history by early
(localized) versus advanced (regional plus distant) stage
tumors (excluding unknown, p¼ 0.49) or by grade
(excluding unknown, p¼ 0.28).
Associations of prostatitis and BPH with prostate cancer
After adjusting for age, race, education, and family
history of prostate cancer in first degree relatives, the
odds of prostate cancer among men with a history of
prostatitis were nearly twice that of men without a
history of prostatitis in the entire sample (OR¼ 1.8,
95% CI: 1.1, 2.9) (Table 3). After stratifying by race, the
odds of prostate cancer among men with a history of
prostatitis were twice the odds of those without a history
of prostatitis in African American men (OR¼ 2.2, 95%
CI: 1.1, 4.6). There was no evidence for interaction
between race and history of prostatitis (p for interaction
term¼ 0.57).
The odds of prostate cancer among men with a history
of BPH were over twice the odds of men without a
history of BPH (OR¼ 2.4, 95% CI: 1.8, 3.3), after
adjusting for age, race, education, and family history of
prostate cancer in first degree relatives (Table 3). After
stratifying by race, the odds of prostate cancer among
men with a history of BPH were more than twice the
odds of those without a history of BPH in both African
American (OR¼ 2.7, 95% CI: 1.6, 4.4) and white
(OR¼ 2.3, 95% CI: 1.5, 3.4) men. There was no
evidence for interaction between race and history of
BPH (p for interaction term¼ 0.84).
Men in this study with a history of BPH were over six
times as likely to have undergone TURP compared to
those without a history of BPH (OR¼ 6.4, 95% CI: 4.0,
10.1) (data not shown). Among the 342 men with a
history of BPH there was no significant association
between TURP and prostate cancer (OR¼ 0.9, 95% CI:
0.5, 1.6)
For a considerable proportion of cases (22.9%) and
controls (22.5%), at least one other individual was
present during their interview. The analyses were
repeated after excluding 296 subjects who had someone
else present during their interview and 51 subjects for
whom this information was not recorded by the inter-
viewer. For all odds ratios presented in Table 3, the
estimates did not differ by more than 10%, and the
directions of the effects were unchanged (data not
shown).
Associations of vasectomy with prostate cancer
Odds ratios for history of vasectomy, age at vasectomy,
and interval since vasectomy are shown in Table 4.
Because only six African American subjects (three cases,
three controls) reported a history of vasectomy, these
analyses combined African American and white sub-
jects. All odds ratios were adjusted for age, race,
education, and family history of prostate cancer in first
degree relatives. A history of vasectomy was reported by
72 cases (10.3%) and 92 controls (15.2%). There was no
significant association between vasectomy history and
Table 4. Odds of prostate cancer by age at and interval since
vasectomy. Wayne County, Michigan, April 1996–March 1998a
Vasectomy Cases Controls ORb 95% CIc
(n = 700) (n = 604)
Never (referent) 627 512 1.0
Ever 72 92 1.0 0.7, 1.5
(Don’t know) (1) (0)
Age at vasectomy (years)
£34 (referent: never) 32 31 1.2 0.6, 2.3
35–39 10 25 0.6 0.4, 0.9
40–44 8 18 0.9 0.6, 1.3
‡45 21 17 1.2 1.0, 1.5
(Missingd) (1) (1)
Interval since vasectomy (years)
£14 (referent: never) 7 14 1.3 0.4, 4.1
15–19 9 11 1.0 0.6, 1.7
20–24 25 30 1.1 0.9, 1.3
‡25 27 33 0.9 0.8, 1.1
(Missinge) (4) (4)
aTable adapted from Lesko et al. [37] and Cox et al. [38].
bOdds ratios (OR) are adjusted for age (as a continuous variable),
race, education, and family history of prostate cancer (first degree
relatives), and do not include subjects with missing covariate data.
cCI, confidence interval.
dNot enough information to calculate age at vasectomy for these
individuals.
eNot enough information to calculate interval since vasectomy for
these individuals.
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prostate cancer (OR¼ 1.0, 95% CI: 0.7, 1.5), after
adjusting for covariates in the model. Age at vasectomy
was not significantly associated with prostate cancer
with the exception that men who had a vasectomy
between ages 35 and 39 had lower odds of prostate
cancer as compared to men without a history of
vasectomy (OR¼ 0.6, 95% CI: 0.4, 0.9). Interval since
vasectomy was not significantly associated with prostate
cancer. No trend of increasing prostate cancer odds with
successively younger ages at or longer intervals since
vasectomy was observed.
Discussion
In this study we examined associations between prostate
cancer and STDs, prostatitis, BPH, and vasectomy. A
strength of the study was the inclusion of a large number
of African American prostate cancer cases and popula-
tion-based controls, which enabled us to assess the
effects of potential risk factors both in the entire study
sample and among African American and white men. A
number of studies have examined STD history in
relation to risk of prostate cancer, reporting mixed
findings. Research has focused primarily on gonorrhea,
syphilis, chlamydia, herpes simplex virus (HSV), and
HPV. Hayes et al. conducted one of the largest popu-
lation-based case–control investigations of STDs and
prostate cancer to date, and found that cases were more
likely to report a history of gonorrhea or syphilis
(OR¼ 1.6, 95% CI: 1.2, 2.1), to show serological
evidence of syphilis (OR¼ 1.8, 95% CI: 1.0, 3.5), and
to have a higher frequency of gonorrhea episodes (p for
trend¼ 0.009) [7]. Another population-based case–con-
trol study reported a borderline significant increased risk
of prostate cancer among men with prior gonorrhea
infection (OR¼ 1.5, 95% CI: 1.02, 2.18) [6], whereas no
evidence for gonorrhea as a risk factor for prostate
cancer was found in a hospital-based case–control study
conducted among men in Greece [44]. Two population-
based case–control studies examining the relationship
between chlamydia infection and prostate cancer did not
report significant associations [6, 8]. HPV, in particular,
has generated interest due to its strong association with
other genitourinary cancers; associations of HPV with
prostate cancer have been reported in some studies [8, 9]
but not others [6, 45–47].
In the late 1980s Ross et al. conducted case–control
studies of prostate cancer risk factors among African
American and white men in California to elucidate
reasons for the differential in prostate cancer risk in
these two racial groups [20]. The authors found an
elevated risk of prostate cancer in both African Amer-
ican (relative risk (RR)¼ 1.7) and white (RR¼ 2.3) men
with a history of STD, with the RR achieving statistical
significance in African American men. Significant dif-
ferences in sexual activity factors, including frequency of
sexual intercourse, age at first sexual intercourse, and
number of spouse’s pregnancies, were also proposed as
possible explanations for the increased risk of prostate
cancer among African American men. More recently, it
has been suggested that the higher incidence rate of
prostate cancer in African Americans may be partially
due to a greater prevalence of oncogenic viral DNA in
prostatic tissues [47].
Our results do not indicate an important role for
sexually transmitted agents in the etiology of prostate
cancer; however, there are several potential limitations
that should be considered in the interpretation our
findings. It is conceivable that stronger associations
between STD history and prostate cancer may exist
among men with an advanced stage of disease at
diagnosis. However, the majority of cases in our study
had localized tumors (79.1%), so we were not able to
conduct a complete analysis of the men with advanced
tumors. We did not have information on timing of
infections; thus, if the relevant window of exposure is
either earlier or later in life, our study may have
attenuated the true associations between these infections
and prostate cancer. We relied on self-report of past
history of STD, which is difficult to validate and may be
limited by a subject’s ability to recognize asymptomatic
infection or recall the event, reluctance to admit a
stigmatic condition, or lack of awareness of a specific
diagnosis made in the past. Moreover, information on
STD history is subject to social desirability bias, that is,
subjects may be inclined to provide answers they believe
are more socially acceptable to others present at
interview. To address the potential for bias in STD
reporting, we repeated the analyses after excluding
subjects who had someone else present during their
interview. Though the absence of another person during
the interview does not preclude misclassification of
exposures with in-person interviews, it was useful to
note that the associations between prostate cancer and
history of STD, prostatitis and BPH were essentially
unchanged after the exclusions.
The high non-participation rate (ratio of interviewed
to total potentially eligible men) may limit the general-
izability of the results obtained from the final study
sample. We note that there is some evidence for different
participation rates in our cases and controls by age and
race. Although we adjusted for these variables in our
analyses, nevertheless the adjustment may not com-
pletely account for this potential bias or other uncon-
trolled selection forces which may have affected our
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study findings. In order to enrich our study population
with older controls, a random sample of Medicare
recipients aged 65–74 years with working telephone
numbers obtained from a HCFA listing was used in
addition to RDD controls. We cannot exclude the
potential for a selection bias if those HCFA controls
with working telephone numbers that we were able to
contact and interview somehow differed from potential
controls without working telephone numbers. The
interval between identification of cases through the
rapid reporting system and date of interview was
substantial, for several reasons. Our study population
included older, urban men, a group that may be more
difficult to reach for interviews. Additionally, obtaining
physician consent prior to contacting cases for interview
and errors in initial contact information obtained
through the rapid reporting system contributed to
delays in interviewing cases. Several measures to
enhance the quality of the study were instituted,
including the use of rapid reporting data updates and
reverse telephone directories to correct errors in contact
information.
Our study demonstrated that prostate cancer cases
were nearly twice as likely to have a history of prostatitis
compared to controls, and a similar, significant associ-
ation was also evident in African American men. No
interaction between race and history of prostatitis was
observed. The observed positive association between
prostatitis and prostate cancer in our study (OR¼ 1.8,
95% CI: 1.1, 2.9) was consistent with results of a recent
study by Roberts et al. (OR¼ 1.7, 95% CI: 1.1, 2.6) [21].
A potential mechanism of carcinogenesis involving
repeated tissue damage and regeneration in the presence
of highly reactive oxygen and nitrogen species lends
biological plausibility to the association between pros-
tatitis and prostate cancer [48]. Our results could reflect
either an etiological connection between prostatitis and
prostate cancer or could reflect a detection bias; many
men with elevated serum prostate-specific antigen levels
undergo prostate biopsy for evaluation for possible
prostate cancer; based on histological criteria, prostatitis
is the most common noncancer diagnosis [49]. The
epidemiological literature on the association between
chronic prostatitis and risk of prostate cancer is limited,
largely due to the difficulty in characterizing this clinical
entity and the lack of a valid practical definition [50]. It
is also unclear whether chronic inflammation influences
prostate cancer initiation, promotion, or both processes
[51]. In our study, we are not aware if men with
prostatitis were diagnosed by a urologist or primary care
physician, and there may be differences in the diagnostic
approach used by these types of physicians [15]. Fur-
thermore, self-reported prostatitis information was not
adequate to determine whether the prostatitis episodes
were acute or chronic, bacterial or nonbacterial, so we
were limited to the broad classification of ‘‘prostatitis’’
as a covariate of interest for prostate cancer. There is
some potential for misclassification of exposure status
due to the lack of clear-cut diagnostic criteria and the
overlap between symptoms of prostatitis and BPH.
However, identifiable correlates of prostatitis do exist
(such as age, severe lower urinary tract symptoms, high
stress, and history of vasectomy and STD), and their
inclusion in future studies should enhance recognition of
this condition and help distinguish it from BPH. Using
data from the Health Professionals Follow-Up Study,
Collins et al. reported that men with a history of BPH
had 7.7-fold greater odds (95% CI: 7.2, 8.3) of prosta-
titis compared to men without BPH history [15]. Studies
that distinguish between acute bacterial, chronic bacte-
rial, and nonbacterial prostatitis, though difficult and
expensive to undertake, could enhance our understand-
ing of the potential infectious and inflammatory roles
for prostatitis in prostate cancer risk.
Our study also suggested that prostate cancer cases
were more than twice as likely to have a past history of
BPH, both overall (OR¼ 2.4, 95% CI: 1.8, 3.3) and
within African American (OR¼ 2.7, 95% CI: 1.6, 4.4)
and white (OR¼ 2.3, 95% CI: 1.5, 3.4) men. No
interaction between race and history of BPH was
observed. As discussed above in relation to prostatitis,
the observed association could be a result of referral bias
or detection bias. Men seen by urologists may be
screened more vigilantly and, thus, may be more likely
to be diagnosed with another urological condition. Men
who are diagnosed with BPH may be subject to
additional medical care and may be more closely
followed up for other prostate problems, including
prostate cancer. TURP is a common surgical treatment
for BPH and could explain the observed association
between BPH and prostate cancer. Incidental detection
of prostate cancer through TURP is thought to explain
slightly less than ten percent of all detected cases [52]. In
the current study, we did not find a significant associ-
ation between TURP and prostate cancer among men
with a history of BPH. A recent review of the epidem-
iologic literature found no relationship between BPH
and prostatic adenocarcinomas arising in the peripheral
zone and weak evidence between BPH and prostatic
adenocarcinomas originating in the transition zone [53];
a much more likely explanation for our findings is that
BPH and prostate cancer share common predisposing
factors.
Overall, we found no significant association between
history of vasectomy and prostate cancer, with the
exception that men who had a vasectomy between 35
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and 39 years of age had decreased odds of prostate
cancer (OR¼ 0.6, 95% CI: 0.4, 0.9). Previous studies
have suggested an elevated risk of prostate cancer
among men who underwent vasectomies at younger
ages, but the observed effects were not statistically
significant [36, 39]. It would be expected that differential
surveillance for and/or detection of prostate cancer
among men who have undergone vasectomy would
increase the odds of prostate cancer: men who have seen
a urologist for a vasectomy may have subsequently been
exposed to more digital rectal examinations or invasive
procedures used to diagnose prostate cancer [54]. We
were unable to examine associations of vasectomy with
prostate cancer by race because only six African
American men (1%) reported a history of vasectomy
in this study; this is consistent with previously reported
vasectomy rates of 1–2% among African Americans in
the U.S. [40]. The underlying mechanisms by which this
sterilization procedure could influence prostate carcino-
genesis remain unclear, but commonly offered biological
explanations include the potential for this surgery to
alter endocrine function and plasma hormone levels [55]
or a permanent reduction in prostatic secretions follow-
ing vasectomy resulting in prolonged exposure of
prostatic glands to carcinogenic factors present in
prostatic fluid [31]. As prostate cancer is a hormon-
ally-related cancer, it is biologically plausible that
clinical syndromes that influence hormone levels may
affect risk of prostate cancer [50].
A body of evidence for an infectious component to
prostate cancer development has begun to emerge;
however, the inconsistent results of previously con-
ducted studies suggest the need for additional research
in this area. As the carcinogenic effects of chronic
inflammation have been considered in organs including
the liver, esophagus, large bowel, urinary bladder and
gastric mucosa [13, 56], the study of prostatitis in
relation to prostate cancer could shed light on a
potential inflammatory etiology of prostate cancer.
Observed associations between BPH and prostate cancer
may reflect common predisposing factors. Questions
remain as to whether men with a history of prostatitis or
BPH have an increased risk of prostate cancer, whether
the observed association is due to some degree of recall
bias, or whether these men simply undergo more vigilant
prostate cancer screening; future studies should take
into account screening patterns to examine the potential
role of detection and recall bias. The lack of association
between vasectomy and prostate cancer in this study
should be assuring in light of the limited contraceptive
options for men and the widespread practice of vasec-
tomy throughout the world. Prevention efforts could be
enhanced if inflammatory or infectious etiologies are
found to be of importance in the subsequent develop-
ment of prostate cancer.
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